ORIC PHARMACEUTICALS

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

25 11 2024 16:15:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

12 11 2024 16:05:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

04 11 2024 16:15:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 11 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

23 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

09 10 2024 16:15:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04 10 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 9 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

26 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

12 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

05 8 2024 16:15:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 8 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

16 7 2024 16:59:15 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 7 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 6 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

29 5 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

06 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 5 2024 16:30:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

15 4 2024 16:15:00 提供 Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

08 4 2024 08:00:00 提供 Nasdaq GlobeNewswire